Onco Actu du 18 mai 2017 - Spécial ASCO

	5.5.1.1 ASCO (général) - Industriels
Pfizer Oncology to Present Data Across 13 Different Types of Cancer at ASCO 2017 Annual Meeting [Pfizer] Data to be presented on more than 15 clinical-stage assets in both solid and hematologic tumors.
Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio [Amgen] First Randomized Study to Evaluate the Combination of IMLYGIC® (talimogene laherparepvec), an Oncolytic Viral Immunotherapy, With a Checkpoint Inhibitor to be Presented.
Data from Clinical Studies of NewLink Genetics' Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017 [NewLink Genetics] "The IDO pathway is a key immuno-oncology target and NewLink Genetics has two separate and distinct IDO pathway inhibitors in clinical development: indoximod and navoximod.
Roche presents the first Phase I efficacy and safety data on CEA-TCB (CEA CD3 TCB), a novel T-cell bispecific antibody targeting solid tumours [Roche] CEA-TCB was studied in patients with carcinoembryonic antigen (CEA)-positive solid tumours, including microsatellite stable (MSS) metastatic colorectal cancers (mCRC) that overexpress CEA and progressed after at least two prior chemotherapy regimens.
Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017 [BMS] BMS compounds to be featured in more than 80 presentations spanning 20 types of cancer, with focus on research of precision therapies aimed at improving standards of care.
Lilly to Present Results from Pivotal Breast Cancer Study of Abemaciclib and New Portfolio Data at ASCO 2017 [Lilly] First presentation of Phase 3 MONARCH 2 study of abemaciclib in combination with fulvestrant in patients with HR+, HER2- advanced breast cancer who progressed on endocrine therapy.
ASCO 2017: Janssen to Present 19 Abstracts in Prostate Cancer and a Spectrum of Blood Cancers; Includes Data on Abiraterone Acetate, Daratumumab and Ibrutinib [Janssen] Phase 3 pivotal trial results for abiraterone acetate selected to be featured in the ASCO Plenary Session and Press Program.
AbbVie to Present Latest Clinical Study Results in Hematology and Solid Tumor Research at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting [AbbVie]
Astellas Announces Oncology Portfolio Updates [Astellas] Astellas is presenting a record number of abstracts at ASCO, including data for gilteritinib in acute myeloid leukemia, enfortumab vedotin in urothelial cancer, and IMAB362 from the recently acquired Ganymed.
Incyte gets a boost from a series of positive data snapshots for its epacadostat/Keytruda combo [EndPoints] The big preliminary winner — not a big surprise — was Incyte, with a slate of new data points underscoring the potential of its leading, late-stage IDO1 drug epacadostat in combination with Merck’s Keytruda.
	5.5.10 ASCO (hémato)
bluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting [bluebird bio] Presentation will include safety and efficacy data from 18 patients with up to 12 months of follow-up.
Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract [The Street] Is the shorter duration of response shown today with enasidenib a potential cause for concern with FDA?
GlycoMimetics stock rockets up on the latest ‘breakthrough’ title in cancer R&D [EndPoints] Now in the Phase II portion of the study, investigators for the company have been recruiting two groups of AML patients: Treatment resistant subjects and newly diagnosed patients over the age of 60. The drug is designed to target pathways tumors use to defend against therapies, heightening the effect of chemo.
Celgene leukemia drug extends survival in early stage trial [Reuters] The drug, enasidenib, delivered high overall response rates in patients with acute myeloid leukemia (AML) whose disease had relapsed following prior treatments. Available data from 176 patients showed 40.3 percent responded to the treatment, with 19.3 percent achieving complete remission.
	5.5.12 ASCO (médico-éco)
More Cancers Diagnosed at Early Stage Following Increase in Health Insurance Coverage [ASCO] An analysis of nearly 273,000 patients showed that between 2013 and 2014 there was a 1% increase in the percentage of breast, lung, and colorectal cancers diagnosed at the earliest, most treatable stage.
Obamacare Helped Americans Detect Cancer Earlier [Bloomberg] While the effect was small, the study found that a higher proportion of new breast, lung and colorectal tumors were detected at stage 1 in 2014 compared with a year earlier.
	5.5.13 ASCO (divers)
Can cashews keep colon cancer patients alive? Study says yes — but cautions abound [STAT] If the benefit is real, a daily handful or two of cashews (cost: less than $1) could work as well as standard chemotherapy (cost: thousands of dollars). But the reported benefit comes with a big “if.”
HPV Vaccination May Reduce Oral HPV Infections – But Still Under-Utilized [ASCO] The authors based their study of oral HPV infections by assessing data from part of the National Health and Nutrition Examination Survey (NHANES) of Americans from 2009 through 2016.
Chance of Colon Cancer Recurrence Nearly Cut in Half in People Who Eat Nuts [ASCO] An observational study of 826 patients with stage III colon cancer showed that those who consumed two ounces or more of nuts per week had a 42% lower chance of cancer recurrence and 57% lower chance of death than those who did not eat nuts.
Vaccine may cut HPV infections, an oral cancer risk, in men [AP] The results in men were striking — no infections in the vaccinated group versus 2.13 percent of the others. The study was observational, so it can’t prove the vaccine was responsible. But it may no longer be ethical to do an experiment where one group gets no vaccine, because its benefits for preventing other cancers is known.
Eating tree nuts may cut risk that colon cancer will return: study [Reuters] The researchers analyzed a questionnaire about dietary intake from a clinical trial of 826 patients with stage III colon cancer - a stage in which the cancer has spread to nearby lymph nodes but not other parts of the body.
	5.5.14 ASCO (vessie)
Merck says test shows Keytruda improves survival for bladder cancer patients [Reuters] Merck said data from an open-label Phase 3 trial of 542 advanced bladder cancer patients showed median survival of 10.3 months for Keytruda patients and 7.4 months for patients given second-line chemotherapy. The study's median follow-up was 18.5 months.
	5.5.17 ASCO (pancréas)
Halozyme Phase 2 Data In Advanced Pancreas Cancer To Be Featured In An Oral Presentation At ASCO [Halozyme] HALO-202 Study Met Primary, Key Secondary Endpoints and Demonstrated a Statistically Significant Improvement in Progression-Free Survival (PFS) in Patients with High Levels of Hyaluronan.
	5.5.2 ASCO (sein)
Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting [Puma] For the 16 patients who were evaluable for efficacy, the objective response (CR/PR) rate was 56%.
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting [Puma] The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study to evaluate the safety and efficacy of PB272 administered daily to patients who have solid tumors with activating HER2 or HER3 mutations.
Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting [Puma] Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).
Pfizer drug from Medivation deal shows promise in breast cancer: study [Reuters] Talazoparib led to significant tumor shrinkage in 21 percent of the 48 patients in the study's first group, whose disease had progressed following platinum-based chemotherapy treatment.
	5.5.4 ASCO (immunothérapies)
Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 and JCAR014 at the 2017 American Society of Clinical Oncology Annual Meeting [Juno] JCAR017 and JCAR014 are chimeric antigen receptor (CAR) T cell product candidates that target CD19, a protein expressed on the surface of almost all B cell malignancies, including non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL).
Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the 2017 American Society of Clinical Oncology Annual Meeting [Kite] "The translational insights from these data presentations are invaluable as we advance axicabtagene ciloleucel/KTE-C19 and seek to optimize treatment, not only in NHL, but also across a broad range of hematologic malignancies."
Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting [The Street] Investors, however, won't find much new CAR-T data in the ASCO research abstracts released Wednesday night.
	5.5.5 ASCO (gastro-intestinal)
Healthy Lifestyle After Colon Cancer Diagnosis Helps Patients Live Longer [ASCO] Over a median follow-up of 7 years, the 91 survivors who had the highest healthy lifestyle scores (5-6 points) had a 42% lower risk of death and a trend for reduced chance of recurrence than the 262 survivors with the lowest lifestyle scores (0-1 points).
	5.5.7 ASCO (gynéco)
ImmunoGen Announces New Clinical Data with Mirvetuximab Soravtansine in Ovarian Cancer to be Presented at 2017 ASCO Annual Meeting [ImmunoGen] Pooled analyses of Phase 1 expansion cohorts demonstrate clinically meaningful activity in patient population being studied in FORWARD I registration trial.
ImmunoGen drug moving ahead in single-agent, combination trials [Reuters] For its pivotal trial, ImmunoGen is enrolling only patients with platinum-resistant disease and medium or high levels of a biomarker known as folate receptor alpha who have received up to three prior lines of therapy. Of the 36 trial earlier-stage trial patients meeting those criteria, 47 percent responded to the drug and median progression-free survival was 6.7 months.
	5.5.8 ASCO (poumon)
Targeted Therapy Can Delay Recurrence of Intermediate-Stage Lung Cancer [ASCO] In a phase III clinical trial, patients with epidermal growth factor receptor (EGFR)-positive, stage II-IIIA non-small cell lung cancer (NSCLC) who received gefitinib went about 10 months longer without recurrence than patients who received chemotherapy.
Merck Keytruda-Chemo ASCO '17 Update Shows Lung Cancer Survival Trend [The Street] The survival benefit was not statistically significant, in part because 75% of the patients randomized into the chemotherapy arm crossed over to receive Keytruda.
Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle [EndPoints] Syndax has been recruiting two different cohorts for the study: PD-1 or PD-L1 treatment naive non-small cell lung cancer patients and NSCLC patients who had seen the disease progress after checkpoint treatment.
Merck, Incyte immunotherapy combination effective in lung cancer study [Reuters] Fourteen of 40, or 35 percent, of patients with advanced non-small cell lung cancer (NSCLC) who received Keytruda and Incyte's epacadostat experienced tumor shrinkage of at least 30 percent.
	5.5.9 ASCO (autres organes)
Drug improves survival of patients with rare cancer by almost a quarter [Cancer Research UK] In the study, around half of the 450 patients were given capecitabine for six months after surgery, and the other half only had surgery.
Oral Chemotherapy Extends Survival by More Than a Year in Biliary Tract Cancer [ASCO] A phase III randomized clinical trial of 447 patients with biliary tract cancers (BTCs, cancers of the bile duct and gallbladder) showed that giving capecitabine after surgery extends survival by a median of 15 months compared to surgery alone. The finding could provide the basis for a new standard of care in the disease.